Glenmark Launches Phytonadione Injectable Emulsion in the U.S.

Glenmark Pharmaceuticals announced on Tuesday, January 21, the launch of its Phytonadione Injectable Emulsion USP, 10 mg/mL, in the U.S. market through its American subsidiary. The single-dose ampules are bioequivalent and therapeutically equivalent to Vitamin K Injectable Emulsion USP, 10 mg/mL, by Hospira, Inc.

Treatment for Vitamin K Deficiency

Phytonadione Injectable Emulsion is used to address blood clotting disorders caused by Vitamin K deficiency. Speaking on the launch, Marc Kikuchi, President and Business Head of Glenmark’s North American operations, said, “We are excited to announce the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”

Results for Trispecific TREAT Antibody ISB 2001

In related news, Glenmark shared encouraging clinical data from its Phase 1 study of the Trispecific TREAT Antibody ISB 2001, targeting patients with heavily pretreated Multiple Myeloma. Initial results from 20 patients, as of October 1, 2024, revealed an overall response rate (ORR) of 75% across all tested doses ranging from 0.005 to 1.2 mg/kg.

The stringent complete remission (sCR) and complete remission (CR) rates stood at 20%. Glenmark highlighted that ISB 2001 data could compare favourably with existing bispecific treatment options, showcasing durable responses and a favourable safety profile.

Stock Reaction

On January 21, 2025, Glenmark Pharma share price traded up by 0.47% at 10:28 AM (IST) at ₹1,511.25. Glenmark Pharma’s share price reached a 52-week high of ₹1,830.05 on October 15, 2024, and a 52-week low of ₹766.65 on February 15, 2024. As per BSE, the total traded volume for the stock stood at 3,016 shares with a turnover of ₹46.07 lakhs.

At the current price, Glenmark Pharma shares are trading at a price-to-earnings (P/E) ratio of 7.56x, based on its trailing 12-month earnings per share (EPS) of ₹199.94, and a price-to-book (P/B) ratio of 1.68, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.